Pharmocogenetics of GABAergic mechanisms of benefit and harm in epilepsy: a cohort and case control study to determine environmental and genetic factors associated with response to clobazam.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

04 Mar 2010 United Kingdom Clinical Research Network reports accrual to date changed from 86% to 91%.
30 Apr 2009 Planned end date changed from 31 Dec 2007 to 1 Aug 2009 as reported by United Kingdom Clinical Research Network.
10 Feb 2009 New source identified and integrated (United Kingdom Clinical Research Network record 6334).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com